Formulation and evaluation of inclusion complexed repaglinide with β-cyclodextrin transdermal patches

Abstract

Chronic diseases such as diabetes mellitus have high prevalence all over the world. The purpose of the study is to prepare a transdermal patch that can be used to treat diabetes, reducing pill burden and increasing patient compliance. Based on positive results of a feasibility study, including doctor’s opinion and prescription survey, repaglinide was selected as the active ingredients for developing a transdermal patch. The complexation of repaglinide and β cyclodextrin was done by grinding method. The present study was designed to develop Matrix type systems of transdermal patch containing repaglinide- β cyclodextrin complexes, using different polymeric combinations such as Hydroxy Propyl Methyl cellulose (HPMC), Ethyl Cellulose (EC), and Eudragit L100 with Poly vinyl pyrolidone (PVP) by solvent evaporation technique. The patches were subjected to physicochemical parameters, in-vitro drug release and in-vitro skin permeation studies. Good results were obtained in all the evaluated parameters. The developed transdermal delivery system containing complex of repaglinide and β cyclodextrin can further be studied for launching it in market.